Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization

Abstract

Common chronic diseases represent the greatest driver of rising healthcare costs, as well as declining function, independence, and quality of life. Geroscience-guided approaches seek to delay the onset and progression of multiple chronic conditions by targeting fundamental biological pathways of aging. This approach is more likely to improve overall health and function in old age than treating individual diseases, by addressing aging the largest and mostly ignored risk factor for the leading causes of morbidity in older adults. Nevertheless, challenges in repurposing existing and moving newly discovered interventions from the bench to clinical care have impeded the progress of this potentially transformational paradigm shift. In this article, we propose the creation of a standardized process for evaluating FDA-approved medications for their geroscience potential. Criteria for systematically evaluating the existing literature that spans from animal models to human studies will permit the prioritization of efforts and financial investments for translating geroscience and allow immediate progress on the design of the next Targeting Aging with MEtformin (TAME)-like study involving such candidate gerotherapeutics.

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms

“…Whether this kind of trial will become more common in the future is unknown. If so, we postulate that SGLT-2i are the perfect candidate for such a study, as has also been suggested by others [ 108 ].…”

New horizons in life extension, healthspan extension and exceptional longevity

“…In the case of gerotherapeutics, an innovative process involving detailed analysis of clinical and preclinical effects on lifespan, healthspan and ageing biology found nine drugs that could potentially be repurposed for their ageing or ‘gerotherapeutic’ effects. These were: sodium-glucose cotransporter-2 (SGLT2) inhibitors, metformin, acarbose, rapamycin/rapalogs, methylene blue, ACEi/ARB, dasatinib (and quercetin), aspirin and N -acetyl cysteine [ 10 ]. Metformin, rapamycin and the combination of dasatinib and quercetin have already been extensively studied for their effects on ageing.…”

Multimorbidität im Versorgungsalltag – Definitionen, Strategien und Grenzen

“…1 Multimorbidität-Cluster von Padros-Torres et al Unterteilung in 3 Krankheitscluster (Spaltenüberschriften), mit den "führenden" Erkrankungen (Zeile 1) und den am häufigsten im Kontext auftretenden Erkrankungen (Zeile 2) [11]. Neben den aktuell bestehenden Therapiemöglichkeiten bilden sich in der Alternsforschung neue Ansätze: Das Forschungsgebiet der Geroscience befasst sich mit dem Alter, dem wichtigsten modifizierbaren Risikofaktor für Multimorbidität [19], [20]. Das Ziel ist die Verlängerung der gesunden Lebenszeit (healthspan, ▶ Abb.…”

“…Hierdurch ergibt sich eine Kompression der Morbiditätsphase in die letzten Lebensjahre hinein. Die Frage, ob damit auch eine gleichzeitige Verlängerung der Lifespan einhergeht, ist Gegenstand aktueller Forschungsarbeiten [20].…”